Medical Developments International Limited Overview
Medical Developments International is a Melbourne-based specialty pharmaceutical and medical device company. Its value rests on one proprietary asset, Penthrox (inhaled methoxyflurane), a fast-acting, non-opioid, self-administered analgesic for trauma and procedural pain, which it manufactures in Scoresby and Springvale, Victoria. Penthrox is the standard of care across Australian ambulance services and is gaining ground in hospital emergency departments. It is sold through partners in the UK, Ireland, the Nordics, France, Switzerland, Canada and more than 20 other markets. A second segment, Respiratory, sells asthma and COPD spacers, peak flow meters, nebulisers and masks in Australia and the US. After a costly FY21–FY24 phase of direct-market expansion, US FDA ambitions, China trials and A$16.4m of impairments, management under CEO Brent MacGregor reset the business to a capital-light, partner-led model with price discipline. The result was EBITDA-positive FY25 and FY26, free cash flow of A$4.2m in FY26, A$21.4m of cash and no debt. The investment case now depends on whether paediatric-label approval in Europe and emergency-department adoption can accelerate volume.
Company's own description (latest annual report, FY26)
In its FY26 Directors' Report, MVP describes its principal activity as providing emergency medical solutions aimed at better patient outcomes in Australia and overseas. It manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product used in hospital emergency departments, ambulance services and sports medicine, and for analgesia during short surgical procedures. It also distributes respiratory devices for people with asthma and COPD [S1]. The standard company boilerplate adds that MVP is a leader in emergency pain relief and respiratory products. It lists Penthrox users as Australian hospitals including emergency departments, ambulance services, the Australian Defence Force and sports medicine, plus analgesia for short procedures such as burns dressing changes, biopsies and dental procedures [S2].
Independent characterisation
MVP is a single-molecule specialty pharma company with a small medical-device distribution business attached. Penthrox generated 74% of FY26 revenue (A$31.6m of A$42.6m) and earned almost all segment profit (Pain Management segment EBIT A$9.4m against Respiratory A$0.7m) [S1]. The business has four structural features:
-
Vertically integrated manufacturer of a niche, hard-to-replicate product. Methoxyflurane is an old volatile anaesthetic. It was withdrawn from anaesthetic use at high doses in the 1970s because of renal toxicity, but at the low analgesic doses in the 3 mL Penthrox inhaler it has a long safety record in Australian pre-hospital care. MVP makes the drug product and device in-house in Victoria. The regulatory dossier (EU Decentralised Procedure, UK, Canada and others), manufacturing know-how and pharmacovigilance history act as barriers to entry, which matters because patent protection on the molecule itself is not a meaningful moat.
-
Hybrid commercial model. In Australia MVP sells Penthrox directly to ambulance services, hospitals and procedural/other segments (Australia was 57% of Pain Management revenue in FY26). Everywhere else it sells to exclusive in-country distribution partners at transfer prices. Partners hold the market authorisations or promotional rights and set in-market price. Since 1 May 2025 (Switzerland, Labatec) and 1 July 2025 (France, Ethypharm), the company has had no direct in-market European commercial operation [S3].
-
Revenue model. Almost entirely product sales, recognised on transfer of control. A small stream of licensing and milestone income comes from upfront partner payments that are deferred and amortised over contract terms: A$0.5–0.6m recognised in FY26, A$0.2m in FY25, and A$0.85m still deferred at 30 June 2026, mainly for Thailand distribution [S1]. There is no subscription or service revenue. Approximate FY26 mix: product sales about 98.6%, amortised milestone/licence income about 1.4% (derived).
-
Value chain position. MVP sits in manufacturing (Penthrox) and brand-owner distribution (Respiratory devices, which rely on a small number of third-party manufacturers and suppliers [S1]). It has no reimbursement control. In Australia, PBS listing of Penthrox in the Prescriber Bag (Doctor's Bag) supports community/GP access, and a 25% PBS price increase in August 2024 was a major margin driver [S12, S3].
Customer types and end-markets
| End-market | Customer type | Product | Notes |
|---|---|---|---|
| Pre-hospital emergency care | State ambulance services (Australia), NHS ambulance trusts (UK, via partner), European EMS | Penthrox | Used across all Australian ambulance services; Australian ambulance demand +4% in FY26 [S1, S12] |
| Hospital emergency departments | Public and private hospitals | Penthrox | Main growth vector. Australian hospital volume +43% FY25, +28% FY26. 244 purchasing hospitals as of FY24 [S4, S3, S1] |
| Procedural analgesia | Day surgery, women's health, dental, dermatology/cosmetic, burns units | Penthrox | "Other segments" demand +5% in FY26, with growth in procedural segments including women's health [S1] |
| Defence, sports medicine, mining/remote first aid | Australian Defence Force, sports clubs, industrial first aid | Penthrox | Legacy Australian niches |
| Community / primary care | GPs, Nurse Practitioners via PBS Prescriber Bag | Penthrox | Nurse Practitioners added to PBS Prescriber Bag eligibility in Oct 2025 [S2] |
| International partners | Distributors (UK/Ireland, Nordics, France, Switzerland, Canada, Middle East, Asia, South Africa) | Penthrox | One Pain Management customer exceeded 10% of group revenue in FY26 (A$4.7m), probably a European partner (unnamed) [S1] |
| Retail pharmacy / consumer respiratory | Pharmacy wholesalers, retailers, US distribution partners | Respiratory devices | US revenue A$6.1m in FY26; Australia A$3.0m [S1] |
Strategy
Stated strategy (FY26 annual report themes)
| Pillar | FY27 initiatives |
|---|---|
| 1. Accelerate penetration of Penthrox | Unlock value from the paediatric indication in Europe; use health-economic analyses to accelerate hospital adoption; generate additional real-world evidence; strengthen partner engagement |
| 2. Grow Penthrox in new markets and segments | Targeted entry into selected new markets; evaluate US market-entry planning and alternative pathways; evaluate procedural indication expansion in Europe; broader market assessment |
| 3. Enhance margins and deliver operational efficiencies | Keep improving commercial terms to reflect Penthrox's value proposition; disciplined cost management and operational efficiencies |
Management describes the nearer-term focus as increasing Penthrox penetration in existing markets, and the longer-term aim as expanding Penthrox into new markets and segments [S1]. The FY27 priorities are organised under three pillars [S1]:
Strategic initiatives in the last 24 months
| Initiative | Timing | Status / outcome | Source |
|---|---|---|---|
| Capital-light European model: partner transfer in Switzerland (Labatec) and France (Ethypharm) | May / Jul 2025 | Completed. Lower transfer prices, lower cost to serve, partner inventory build in FY26 | S3, S1 |
| UK and Ireland distribution extension to end-2027 on improved terms | Jul 2024 | Effective from FY25 | S4 |
| Paediatric label (6+) in UK and EU | Filed Aug 2024; approved Aug 2025 to Aug 2026 | Approved and launched in all targeted markets | S4, S3, S2 |
| Australian ED penetration program: formulary listings (Queensland LAM listing for all public EDs; South Australia formulary), protocol inclusions, clinician engagement | FY24–FY26 | Hospital volume +43% (FY25) and +28% (FY26) | S3, S4, S1 |
| Health-economic study of Penthrox in EDs | Initiated FY25; published FY26 | Published in Emergency Medicine Australasia; reports whole-of-department cost and operational savings | S3, S1 |
| MAGPIE paediatric study publication | FY26 | Published in Injury | S1 |
| PBS Prescriber Bag access for Nurse Practitioners | Oct 2025 | Effective | S2 |
| Pricing: PBS +25% (Aug 2024); Australian price rise for remaining customers (Jul 2025); US Respiratory price increases | FY25–FY26 | About A$4m (FY25) and about A$1m (FY26) earnings benefit from Australian pricing | S3, S1 |
| Cost program: A$3–4m of FY25 efficiencies after A$7.2m of FY24 pricing and efficiency benefits | FY24–FY25 | Delivered A$4m in cost reductions in FY25 | S4, S3 |
| Incentive plan review | FY27 | In progress; FY26 LTI grants deferred | S1 |
| Climate reporting readiness | From FY28 | Group 3 entity under Australian mandatory climate disclosures | S1 |
Guidance and medium-term targets
FY27 qualitative outlook [S1, S2]:
-
Higher in-market Penthrox demand, supported by the European paediatric indication and the health-economic data.
-
Stable Respiratory demand.
-
No repeat of FY26 inventory-stocking benefits.
-
About A$1m of additional amortisation for capitalised European paediatric registration costs.
-
Uncertain earnings impact from Middle East supply-chain disruption and US tariffs.
-
FY27 capex of about A$1.5m.
No quantitative revenue or EBIT guidance and no medium-term financial targets have been published. In FY23 the company estimated US Penthrox in-market revenue potential at US$300–400m five years after launch, but the US program has been paused since July 2024 [S5, S4].
Products & Services
Pain Management segment
| Product | Description | Key specifications / capabilities | Target customers | Launch / latest version | Pricing model |
|---|---|---|---|---|---|
| Penthrox® (methoxyflurane) inhalation (flagship; "the Green Whistle") | Self-administered, fast-acting, non-opioid inhaled analgesic for trauma and procedural pain | 3 mL methoxyflurane vial with single-use handheld inhaler (with activated carbon chamber to reduce exhaled vapour). Analgesia onset within minutes; patient-controlled intermittent inhalation. Daily and weekly dose ceilings apply under label. Combination product (medicine plus device), so it requires both medicines and device approval in Europe [S3] | Ambulance services, hospital EDs, procedural settings, defence, sports medicine, GPs/NPs (PBS Prescriber Bag) | In Australian use since the 1970s. UK/EU approval mid-2010s for adults with moderate-to-severe trauma pain. Paediatric extension (age 6+) approved in UK and all EU DCP markets by Aug 2026 [S2] | Australia: direct sale at list/contract prices plus PBS-reimbursed Prescriber Bag supply (PBS price +25% Aug 2024). July 2025 increase for remaining customers (about 25% of volume) worth about A$1m in FY26 [S1]. International: transfer prices to partners |
| Penthrox multi-pack / ambulance and hospital packs | Pack configurations for institutional buyers | Configurations: n/d | Ambulance and hospitals | — | Contract pricing |
| Penthrox paediatric indication (label extension) | Extension of the European label from 18+ to 6+ supported by the MAGPIE study | MAGPIE study published in Injury (FY26). HPRA approval Aug 2025; device approval Feb 2026; national approvals including UK by Aug 2026 [S3, S9, S2] | UK ambulance trusts (removes a barrier to entry in some trusts [S3]), European EDs | 2025–2026 | Partner transfer pricing |
| "Selfie" / NextGen Penthrox delivery device (development) | Next-generation inhaler device for ease of use | FY21–FY22 disclosures referred to a planned NextGen launch in Australia, UK and Europe by FY24 and to the "Selfie" device reaching development milestones [S13]. Current status: n/d. Not referenced in FY26 priorities | — | Not launched (status n/d) | — |
Indications pipeline (stated FY27 priorities): procedural indication expansion in Europe (under evaluation), US market entry "alternative pathways" (under evaluation), and real-world evidence generation [S1].
Respiratory segment
| Product line | Description | Target customer | Notes |
|---|---|---|---|
| Spacer chambers (brands historically include Space Chamber Plus® and Breath-A-Tech®; current brand list not re-verified) | Valved holding chambers used with pressurised metered-dose inhalers; anti-static variants; adult and paediatric sizes | Pharmacies, hospitals, US retail/pharmacy channels | Main US growth product. MVP claimed continued US spacer market share gains in FY24 (US revenue +37%) and FY25 [S4, S3]. FY26 US revenue -16% on softer demand despite price increases [S1] |
| Silicone face masks | Masks for spacer use by infants, children and adults | Paediatric asthma | Sold alongside spacers |
| Peak flow meters | Devices for monitoring expiratory flow in asthma management | Patients, GPs, pharmacies | Australian market |
| Portable nebulisers | Compact nebuliser units | Patients, pharmacies | Australian and Asian markets |
The company describes the segment as a leading supplier of spacer chambers, peak flow meters, portable nebulisers and silicone face masks for asthma and COPD patients. It sells into Australia, the US, Europe and Asia through leading distributors [S1].
Pricing model: wholesale/distributor pricing. US pricing initiatives were used in FY26 to offset tariff pressure [S1].
Discontinued / exited portfolios
| Portfolio | Exit date | Notes |
|---|---|---|
| Veterinary products | FY22 | Segment exited [S6] |
| Non-core medical equipment lines | FY22 | Exit of unprofitable, non-core medical lines announced with H1 FY22 results [S13] |
| Continuous-flow manufacturing program (with CSIRO) | FY22 | Program concluded. A CSIRO options reserve of A$1.866m remains in equity [S6, S1] |
| US Penthrox Phase III / NDA program | Paused Jul 2024 | Assets impaired (part of A$16.4m) [S4] |
| China Penthrox program | FY23 | Discontinued; termination revenue recognised [S5] |
Financial Narrative
Income statement: notes and sources
Source: FY26 Remuneration Report five-year performance table [S1]; FY25–FY26 P&L [S1]. FY23 revenue excludes A$18.9m contract termination revenue (A$18.5m China), which is included in reported EBIT [S1]. FY24 reported EBIT includes A$21.5m of underlying adjustments (A$16.4m impairments; A$5.1m non-cash CEO remuneration transition expense), and FY24 NPAT includes a A$15.0m non-cash tax charge from derecognising tax losses [S4].
Margin profile
Notes: Company gross margin of 74% in FY24 is reported as "up 5ppts", which implies about 69% in FY23 [S12]. The company did not restate a gross margin figure in FY25–FY26 releases. The derived proxy uses "raw materials and consumables used" (A$11,896k FY26; A$10,812k FY25) and excludes manufacturing labour, so it is not comparable with company-defined gross margin. FY23 net margin is distorted by termination revenue.
Revenue CAGR FY22–FY26: 18.0% (A$21.9m to A$42.6m, derived). FY24–FY26 CAGR: 13.3% (derived).
FY26 vs FY25 expense structure [S1]
Commentary: The FY22–FY24 period was an expensive build-out. It included direct commercial capability in Europe (France, Switzerland), a US Penthrox regulatory program, a China clinical program and Australian hospital investment, and underlying EBIT losses peaked at A$18.2m in FY23. The inflection came in FY24–FY25 under the "pricing and efficiency" program. FY24 delivered A$7.2m of pricing and efficiency benefits and a 5ppt gross-margin uplift [S4]. FY25 added a further A$4m from pricing (the August 2024 PBS increase and better UK/Ireland terms) and A$4m of cost reductions [S3]. Those changes produced an A$11.6m EBIT turnaround to breakeven. FY26 EBIT was only A$0.3m better, despite A$3.5m more revenue, for three reasons: a A$2.5m adverse FX swing, a deliberate increase in medical and commercial spend, and lower average European selling prices after the shift to partner supply [S1]. Management excluded partner-stocking timing benefits from STI calculations, which suggests that FY26 EBIT on a "clean" basis was weaker than reported [S1].
Balance sheet
Sources: S1 balance sheet, changes in equity (FY24 closing equity A$45,734k) and Note 2.4 (FY24 opening PP&E and intangibles); S12 (cash A$9.7m at 30 June 2024). Earlier cash reference points: A$15.5m (30 Jun 2020), A$36.2m (30 Jun 2021), A$28.3m (31 Dec 2021), and about A$49m pro forma after the August 2022 raise [S13, S6].
Balance sheet commentary: MVP has no financial debt. Its only interest-bearing obligations are property leases of A$1.7m. Equity is A$55.8m, against accumulated losses of A$62.1m and contributed equity of A$115.0m, which shows how much capital the FY21–FY24 investment cycle consumed [S1]. Intangibles of A$21.2m are dominated by A$14.6m of capitalised European registration costs (including the paediatric dossier, which starts amortising at about A$1m a year in FY27) and A$3.8m of Pain Management goodwill. The Pain Management CGU carrying value (A$3.8m goodwill plus A$16.1m other intangibles) was a Key Audit Matter for Deloitte [S1]. Unused Australian tax losses total A$16.0m, of which only A$1.6m is recognised as a DTA [S1]. Working capital fell A$5.2m in FY26 as inventory dropped A$2.5m (lower Respiratory demand and the shift away from holding French stock) [S1].
Cash flow
Notes: FY26 FCF of A$4.2m is company-reported [S1, S2]. FY25 is derived from the stated A$5.8m FY26 improvement. FY24 is derived from the stated A$12.9m FY25 improvement. FY23 is derived from the A$10.2m FY24 improvement; S4 also describes this as +42%, which implies about -A$24.3m, so FY23 is approximate. The August 2022 A$30m raise fell in FY23. The August 2024 A$10m raise fell in FY25 (gross A$10,014k, costs A$736k) [S1, S6]. Employee trust purchases are on-market purchases to satisfy incentive awards, not capital-return buybacks [S1].
FY26 cash-flow bridge (A$000): EBITDA 2,900, plus non-cash items 946, plus working-capital release 2,173, less other movements 558, plus net interest 289, gives operating cash flow of 5,750. After capex 795, leases 319 and the employee share trust 479, company-defined FCF was about 4.2m. A A$7.0m term deposit (5.1%, maturing November 2026) was moved out of cash, so reported cash fell A$3.5m even though total liquidity rose [S1].
Ratios
All ratios are derived from S1. Negative net debt/EBITDA indicates a net cash position. Inventory and payable days use raw materials and consumables as a COGS proxy because the company does not disclose cost of goods sold, so they overstate true days. Read them for direction only. The ratios point to a business that is liquid and unlevered but earns very low returns on its capital base: ROE is about 1% on A$55.8m of equity.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products | Regions of operation (per Note 1.1) |
|---|---|---|---|
Pain Management | Manufacture and sale of Penthrox | Penthrox (methoxyflurane 3 mL with inhaler; multiple pack configurations) | Australia, Europe, United Kingdom, Middle East, Canada, Asia, South Africa |
Respiratory | Sale of respiratory devices for asthma and COPD | Spacer chambers, peak flow meters, portable nebulisers, silicone face masks | Australia, USA, Europe, Canada, Asia, United Kingdom |
Other (unallocated) | Corporate overheads and foreign-exchange gains/losses | — | — |
Revenue by Segment
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Pain Management revenue (AUD K) | 21,300 | 26,190 | 31,620 |
Respiratory revenue (AUD K) | 11,900 | 12,866 | 10,948 |
Group revenue (AUD K) | 33,149 | 39,056 | 42,568 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Margins & Growth (%) and Revenue by Segment (%)
| Segment metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Pain Management YoY revenue growth (%) | 4.0 | 23.0 | 20.7 |
Respiratory YoY revenue growth (%) | 1.0 | 9.0 | -14.9 |
Pain Management share of group revenue (%) | 64.3 | 67.1 | 74.3 |
Respiratory share of group revenue (%) | 35.9 | 32.9 | 25.7 |
Pain Management segment EBITDA (AUD K) | — | 8,821 | 11,376 |
Respiratory segment EBITDA (AUD K) | — | 706 | 1,003 |
Other / corporate EBITDA (AUD K) | — | -6,372 | -9,479 |
Pain Management segment EBIT (AUD K) | — | 6,287 | 9,420 |
Respiratory segment EBIT (AUD K) | — | 430 | 702 |
Other / corporate EBIT (AUD K) | — | -6,765 | -9,907 |
Pain Management EBITDA margin (%) | — | 33.7 | 36.0 |
Respiratory EBITDA margin (%) | — | 5.5 | 9.2 |
Pain Management EBIT margin (%) | — | 24.0 | 29.8 |
Respiratory EBIT margin (%) | — | 3.3 | 6.4 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue, underlying (AUD K) | 21,943 | 32,337 | 33,149 | 39,056 | 42,568 |
Revenue growth (%) | 34.4 | 47.0 | 2.5 | 17.8 | 9.0 |
Underlying EBITDA (AUD K) | -11,724 | -15,133 | -8,237 | 3,155 | 2,900 |
Underlying EBIT (AUD K) | -14,669 | -18,246 | -11,631 | -48 | 215 |
Reported EBIT (AUD K) | -15,850 | -7,957 | -33,142 | -48 | 215 |
Profit before tax (AUD K) | — | — | — | 168 | 504 |
Income tax benefit / (expense) (AUD K) | — | — | — | -74 | 122 |
Statutory NPAT (AUD K) | -12,407 | -5,609 | -40,992 | 94 | 626 |
Basic EPS (A$ cents) | -17.41 | -6.66 | -47.50 | 0.09 | 0.56 |
Diluted EPS (A$ cents) | — | — | — | 0.08 | 0.53 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin, company-reported (%) | — | 69 | 74 | — | — |
Revenue less raw materials and consumables, derived (%) | — | — | — | 72.3 | 72.1 |
Underlying EBITDA margin (%) | -53.4 | -46.8 | -24.8 | 8.1 | 6.8 |
Underlying EBIT margin (%) | -66.9 | -56.4 | -35.1 | -0.1 | 0.5 |
Net margin on underlying revenue (%) | -56.5 | -17.3 | -123.7 | 0.2 | 1.5 |
Income Statement
| Line item | FY2025 | FY2026 |
|---|---|---|
Raw materials and consumables (AUD K) | 10,812 | 11,896 |
Employee benefits expense (AUD K) | 14,771 | 16,006 |
Distribution expenses (AUD K) | 2,188 | 1,602 |
Regulatory and registration expenses (AUD K) | 1,901 | 1,329 |
Occupancy, selling and administration (AUD K) | 7,941 | 7,993 |
Other gains / (losses), mainly FX (AUD K) | 1,626 | -905 |
Depreciation and amortisation (AUD K) | 3,203 | 2,685 |
Interest and other income (AUD K) | 377 | 417 |
Finance costs (AUD K) | 75 | 65 |
Balance Sheet and Per-Share Data
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Cash and cash equivalents (AUD K) | 9,735 | 17,837 | 14,368 |
Term deposits / other financial assets (AUD K) | 0 | 0 | 7,000 |
Total cash incl. term deposit (AUD K) | 9,735 | 17,837 | 21,368 |
Trade and other receivables (AUD K) | — | 7,652 | 6,699 |
Inventories (AUD K) | — | 9,450 | 6,953 |
Plant and equipment incl. right-of-use (AUD K) | 10,162 | 8,938 | 7,729 |
Goodwill (AUD K) | 3,808 | 3,808 | 3,808 |
Goodwill and other intangibles (AUD K) | 22,857 | 21,918 | 21,237 |
Total assets (AUD K) | — | 66,396 | 64,600 |
Borrowings, short-term (AUD K) | 0 | 0 | 0 |
Borrowings, long-term (AUD K) | 0 | 0 | 0 |
Lease liabilities, total (AUD K) | — | 1,990 | 1,667 |
Total liabilities (AUD K) | — | 11,292 | 8,793 |
Total equity (AUD K) | 45,734 | 55,104 | 55,807 |
Net cash incl. term deposit, less leases (AUD K) | — | 15,847 | 19,701 |
Working capital, current assets less current liabilities (AUD K) | — | 27,716 | 29,436 |
NTA per share (A$ cents) | — | 29.5 | 30.7 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD K) | — | — | — | -43 | 5,750 |
Capex, plant and equipment (AUD K) | — | — | — | 443 | 481 |
Capex, intangibles (AUD K) | — | — | — | 597 | 314 |
Lease repayments (AUD K) | — | — | — | 296 | 319 |
Free cash flow, company definition (AUD K) | — | -24,700 | -14,500 | -1,600 | 4,200 |
Dividends paid (AUD K) | 0 | 0 | 0 | 0 | 0 |
Share buybacks, employee trust purchases (AUD K) | — | — | — | 304 | 479 |
Equity raised, gross (AUD K) | — | 30,000 | 0 | 10,014 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2025 | FY2026 |
|---|---|---|
ROE, on average equity (%) | 0.2 | 1.1 |
ROA, on average assets (%) | — | 1.0 |
ROIC, NOPAT at 25% over equity less net cash (%) | -0.1 | 0.4 |
Current ratio (x) | 4.54 | 5.77 |
Debt to equity, incl. leases (x) | 0.04 | 0.03 |
Net debt to EBITDA (x) | -5.0 | -6.8 |
Interest coverage, EBIT over finance costs (x) | -0.6 | 3.3 |
Asset turnover, revenue over average assets (x) | — | 0.65 |
Receivable days (days) | 72 | 57 |
Inventory days, on raw-material cost proxy (days) | 319 | 213 |
Payable days, on raw-material cost proxy (days) | 219 | 149 |
Cash conversion cycle, proxy (days) | 172 | 121 |
Revenue by Region
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia (AUD K) | — | 18,828 | 20,874 |
Europe incl. UK (AUD K) | — | 9,314 | 9,614 |
United States (AUD K) | — | 7,277 | 6,135 |
Rest of World (AUD K) | — | 3,637 | 5,945 |
Total (AUD K) | 33,149 | 39,056 | 42,568 |
Revenue by Region (FY2025–FY2026)
| Segment and region | FY2025 | FY2026 |
|---|---|---|
Pain Management, Australia (AUD K) | 15,427 | 17,909 |
Pain Management, Europe (AUD K) | 8,073 | 9,019 |
Pain Management, United States (AUD K) | 0 | 0 |
Pain Management, Rest of World (AUD K) | 2,690 | 4,692 |
Respiratory, Australia (AUD K) | 3,401 | 2,965 |
Respiratory, Europe (AUD K) | 1,241 | 595 |
Respiratory, United States (AUD K) | 7,277 | 6,135 |
Respiratory, Rest of World (AUD K) | 947 | 1,253 |
Geographic Revenue
| Region | FY2025 share (%) | FY2026 share (%) | FY26 YoY growth (%) |
|---|---|---|---|
Australia | 48.2 | 49.0 | 10.9 |
Europe | 23.8 | 22.6 | 3.2 |
United States | 18.6 | 14.4 | -15.7 |
Rest of World | 9.3 | 14.0 | 63.5 |
Markets
| Market | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australian hospital segment Penthrox volume growth (%) | 30 | 43 | 28 |
Australia total Penthrox volume growth (%) | 3 | — | 9 |
Australia ambulance volume growth (%) | — | — | 4 |
European in-market Penthrox volume growth (%) | — | 15 | 18 |
UK and Ireland in-market volume growth (%) | 3 | — | 20 |
France in-market volume growth (%) | — | — | 11 |
Nordic in-market volume growth (%) | 42 | — | 19 |
US Respiratory revenue growth (%) | 37 | — | -16 |
Share Price and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price at period end (AUD) | 1.46 | 0.78 | 0.39 | 0.55 | 0.39 |
Annual price change (%) | — | -46.6 | -50.0 | 41.0 | -29.1 |
Valuation Multiples
| Multiple | MVP |
|---|---|
Market capitalisation (AUD Mn) | 51.3 |
Enterprise value: market cap less cash and term deposit plus leases (AUD Mn) | 31.6 |
P/E, FY26 basic EPS 0.56c (x) | 81 |
EV / EBITDA, FY26 (x) | 10.9 |
EV / Sales, FY26 (x) | 0.74 |
P / Book (x) | 0.92 |
P / NTA, NTA 30.7c (x) | 1.48 |
Analyst Ratings & Targets
| Broker / source | Rating | Target (AUD) | Date |
|---|---|---|---|
Bell Potter | Positive (target implies about 100% upside) | 1.00 | Aug 2026 [S15] |
TipRanks-aggregated latest rating | Buy | 0.80 | Aug–Sep 2025 [S15] |
Consensus | n/d (Market Index notes no major-broker consensus compilation) | — | 2026 |
Capital Markets
| Item | Status |
|---|---|
Dividend history | No dividends declared for FY22–FY26 [S1]. Small dividends were paid before the investment phase (FY20 yield cited at about 0.6–0.7%) [S15] |
Dividend policy | None stated; capital prioritised for Penthrox growth |
Buyback authorisations | None. Only on-market purchases by the employee share trust (A$0.48m in FY26) [S1] |
Credit ratings (Moody's, S&P, Fitch) | Not rated |
Debt maturity profile | No borrowings. Lease liabilities of A$1.667m (current A$0.343m; non-current A$1.324m) [S1] |
Dilution overhang | 2.30m unvested KMP performance rights plus CSIRO options; diluted share count 117.1m [S1] |
Analyst Conclusions
Management guidance (FY27) [S1, S2]
-
Higher in-market Penthrox demand (paediatric indication; health-economic data).
-
Stable Respiratory demand.
-
No repeat of FY26 partner inventory-stocking benefits.
-
About A$1m of incremental amortisation from capitalised European paediatric registration costs.
-
Middle East supply-chain and US tariff impacts uncertain.
-
Capex of about A$1.5m.
-
No quantitative EBIT or revenue guidance.
Consensus expectations
n/d. Coverage is limited to a small number of brokers, and no published consensus revenue or EPS for FY27 was verifiable.
Bull case
-
The paediatric label is a volume step-change in the UK and Europe. The UK is the largest ex-Australia market. The partner already has listings in over 70% of hospital trusts, and the paediatric label removes a stated barrier to some ambulance trusts [S4, S3]. European in-market volume already grew 18% before the label took effect [S1].
-
Operating leverage on a high-margin core. Pain Management converts about 36% of revenue into EBITDA. If corporate costs stay near A$9–10m, each extra A$5m of Penthrox revenue could add roughly A$1.8m of EBITDA, a meaningful increase on a A$2.9m base (analyst estimate).
-
Optionality at a low valuation. With EV of about A$32m (0.74x sales) and an A$21m cash buffer, a US partnering deal through "alternative pathways", against the company's own US$300–400m US potential estimate, or new-market entries would be value-accretive without needing a capital raise [S5, S1].
Bear case
-
FY26 earnings quality is weaker than reported. Partner stocking, a one-off US tariff refund and lower D&A supported FY26, and the board itself excluded the stocking timing benefits. FY27 also absorbs about A$1m of new amortisation [S1, S2].
-
Growth may be structurally capped. European revenue grew only 12% against 18% volume growth because of lower transfer prices. Australian ambulance (+4%) is mature. Respiratory is shrinking (-15%) and tariff-exposed [S1].
-
Track record of capital consumption. Accumulated losses are A$62m, the company has raised about A$40m since 2022, three successive LTI tranches have failed or are failing, and several international strategies (US, China, direct Europe) have been abandoned [S1, S4, S5].
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Late Oct 2026 | Q1 FY27 Appendix 4C: first read on European paediatric uptake and stocking reversal |
| Oct–Nov 2026 | 2026 AGM: Chair Fladrich's first AGM; incentive-plan review signals |
| Nov 2026 | Maturity of the A$7.0m term deposit (cash reclassification only) |
| Ongoing FY27 | Australian hospital volume growth (sustaining 20%+); NHS ambulance trust adoption; new-market entries |
| Feb 2027 | H1 FY27 results: EBIT trajectory after stocking non-recurrence and new amortisation |
| FY27 | Any US pathway or partnering announcement; procedural-indication decisions in Europe |
| FY27 | US tariff regime and Respiratory demand; Middle East logistics costs |
| End-2027 | UK and Ireland distribution agreement expiry and renewal terms |
Analyst verdict
Medical Developments International has completed a credible operational turnaround but has not yet proved it is a growth company. Between FY23 and FY26 management moved the business from an A$18.2m underlying EBIT loss to modest profit. It did so by repricing Penthrox in Australia, extracting better partner terms, exiting direct European operations, and abandoning capital-hungry ventures in the US and China. The balance sheet is now clean, with A$21.4m of cash, no debt and a self-funding operation. That removes the dilution risk that dominated the share register from 2022 to 2024.
The core asset is valuable. Penthrox has a 36% segment EBITDA margin, decades of safety data and newly expanded paediatric labelling in its most important export market. Clinical and health-economic evidence for emergency-department use is accumulating, and Australian hospital volumes have grown 28–43% a year for three years.
Even so, group profitability is barely positive. A corporate cost base of about A$9.5m absorbs most segment profit, and FY26 results were flattered by partner stocking, a tariff refund and favourable amortisation. FY27 begins with explicit headwinds: no repeat of stocking, about A$1m of new amortisation, and tariff and Middle East uncertainty. Respiratory is a drag that management has not fixed.
At about A$0.45 and an enterprise value of about A$32m (0.7x sales; about 11x a depressed EBITDA), the market is assigning little value to the paediatric opportunity or any US optionality. The equity is therefore an asymmetric but execution-dependent proposition. If in-market European volume growth accelerates beyond 20% in FY27 and Australian hospital momentum continues, operating leverage should become visible and support a re-rating toward broker targets (A$0.80–1.00). If FY27 EBIT turns negative once stocking reverses, the stock is likely to remain a value trap.
Overall stance: speculative positive. Thesis validation hinges on the H1 FY27 result (February 2027).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background | FY26 statutory total (AUD) |
|---|---|---|---|---|
Brent MacGregor | Chief Executive Officer | CEO since 2021 (exact start date n/d) | Education and age: n/d | 1,213,519 |
Anita James | Chief Financial Officer | n/d (KMP for full FY25 and FY26) | Education and age: n/d | 656,626 |
Tara Eaton | Company Secretary and General Counsel | Since 8 Aug 2022 | Former General Counsel, Australian Red Cross; Legal and Compliance Director, Gilead Sciences ANZ; Legal Director, Merck & Co; earlier at Minter Ellison and Clayton Utz. Qualifications: B.As, LLB, LLM, GradDip (Applied Corp Gov), GAICD | Not KMP |
Directors' Remuneration
| Component | MacGregor FY2025 | MacGregor FY2026 | James FY2025 | James FY2026 |
|---|---|---|---|---|
Base salary (AUD) | 620,132 | 645,314 | 360,849 | 373,487 |
STI cash (AUD) | 150,778 | 102,346 | 80,053 | 85,390 |
Other benefits (AUD) | 48,549 | 64,156 | 0 | 0 |
Other long-term benefits (AUD) | 11,081 | 16,911 | 2,855 | 5,297 |
Superannuation (AUD) | 29,932 | 30,000 | 41,498 | 44,818 |
STI equity (AUD) | 150,777 | 102,345 | 80,053 | 85,389 |
LTI, share-based (AUD) | 252,447 | 252,447 | 81,496 | 62,245 |
Total statutory (AUD) | 1,263,696 | 1,213,519 | 646,804 | 656,626 |
Board of Directors
| Name | Role | Appointed | Independent | Committees | Background | Other listed boards | FY26 fees (AUD) |
|---|---|---|---|---|---|---|---|
Mark Fladrich (BPharm, MBA, GAICD) | Non-Executive Chair (since 1 Dec 2025) | 2025 (NED before becoming Chair; exact date n/d) | Yes | ARC, PCC, CDC | Over 30 years in pharma. Former Chief Commercial Officer at Grünenthal, where he expanded the US presence alongside relaunch of a non-opioid chronic pain product. 23 years at AstraZeneca, including VP Global Strategic Marketing and Country President for Germany and Australia/NZ. Also Allergan and Faulding | QBiotics (May 2024 – Nov 2025) | 80,417 |
Leon Hoare | NED; Chair of People and Culture Committee | 27 Sep 2013 | Yes (tenure about 13 years) | PCC (Chair) | Managing Director, Lohmann & Rauscher ANZ to Dec 2025. 24 years at Smith & Nephew, including MD ANZ and President of Asia-Pacific Advanced Wound Management | PolyNovo (since 2016) | 60,000 |
Christine Emmanuel-Donnelly | NED | 26 May 2020 | Yes | ARC | Intellectual property and business development executive. Former Executive Manager of BD and Commercial at CSIRO; patent attorney | Chair of ImpediMed; NED of PolyNovo | 60,000 |
Dr Russell Basser (MD, FRACP) | NED | 1 Sep 2023 | Yes | PCC | Medical oncologist; 21 years at CSL, including Chief Medical Officer and SVP R&D at CSL Seqirus | Starpharma (since 2023) | 60,000 |
Paul Townsend (BBusAcc, FCA, GAICD) | NED | 30 May 2025 | Yes | ARC, CDC | ASX CFO experience at Nufarm, Asaleo Care and Pacific Hydro; also Monash University | — | 60,000 |
Gordon Naylor (former) | Former Chair | Resigned 1 Dec 2025 | — | — | Ex-CSL senior executive; about five years on the board, mostly as Chair | — | 39,583 |
Major Shareholders
| Holder category | Shares | % of 112.66m | Source |
|---|---|---|---|
Non-executive directors (combined) | 304,809 | 0.27 | S1 |
CEO B. MacGregor | 649,251 | 0.58 | S1 |
CFO A. James | 208,317 | 0.18 | S1 |
Unvested performance rights (CEO and CFO) | 2,302,357 | 2.04 (potential) | S1 |
Competitive Landscape
Key Competitors
| # | Competitor / alternative | Company | Setting | Relative positioning vs Penthrox |
|---|---|---|---|---|
| 1 | Nitrous oxide/oxygen 50:50 (Entonox) | Linde plc (BOC) | Ambulance, ED, labour, procedures | Entrenched and cheap per use, but needs cylinders and equipment and has environmental (greenhouse) and occupational exposure concerns. Penthrox is more portable |
| 2 | Nitrous oxide/oxygen (Kalinox and others) | Air Liquide | France and Europe procedures | Strong in France; a competitive barrier to Penthrox's French penetration |
| 3 | Intravenous / intramuscular morphine and generic opioids | Multiple generic manufacturers | ED, ambulance | Standard of care. Needs IV access and carries opioid risks. Penthrox's non-opioid profile and speed are its differentiators |
| 4 | Intranasal fentanyl (e.g. Instanyl; generics) | Multiple (originally Takeda/Nycomed) | Pre-hospital, paediatric ED | Direct competitor in paediatric pre-hospital care, an area the new Penthrox paediatric label now contests |
| 5 | Ketamine (low-dose, IV/IN) | Generic manufacturers | ED, pre-hospital, military | Growing use for trauma analgesia |
| 6 | Sublingual sufentanil (Zalviso / Dsuvia) | — | Acute pain | Non-invasive opioid alternative; niche |
| 7 | IV paracetamol / IV ibuprofen / NSAIDs | Multiple (B. Braun, Fresenius Kabi and generics) | ED | Adjunct or alternative for moderate pain |
| 8 | Methoxyflurane generics / follow-ons | None known to be approved in MVP's core markets | — | Barrier: manufacturing know-how and regulatory dossiers. Any generic entry is a key long-term risk |
| 9 | AeroChamber Plus family | Trudell Medical International (private, Canada) | Valved holding chambers | Global category leader, including the US. MVP is a share-gainer from a small base |
| 10 | OptiChamber Diamond | Philips Respironics | Valved holding chambers | Major US and global player |
| 11 | Vortex spacers, PARI nebulisers | PARI GmbH (private) | Spacers, nebulisers | Strong in Europe |
| 12 | Able Spacer, Mini-Wright peak flow meters | Clement Clarke International (UK) | Spacers, peak flow meters | UK/Europe |
| 13 | Omron nebulisers | Omron Healthcare | Nebulisers | Consumer nebuliser leader |
Competitor Detail
| Metric | MVP (FY26) |
|---|---|
Revenue | A$42.6m |
Revenue growth | 9.0% |
EBITDA margin | 6.8% |
EBIT margin | 0.5% |
R&D intensity | n/d (capitalised about 0.7% of revenue) |
Recent Developments
--



